Findings

What do systematic reviews say?

2,293 questions · 2,395 findings · 172 reviews · Gut

Sort:Best matchNewestHighest certainty Download CSV

No studies found 420 · 17.5%GRADE not reported 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%

Viaskin milk patch vs placebo

Clinical improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Histological improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Histological improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Endoscopic improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Viaskin milk patch vs placebo

Withdrawals due to adverse events · active EoE pediatric patients

Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.12 [0.05, 23.99]
1 study · 20 participants
Low

Leukotriene receptor antagonist vs placebo

Clinical improvement (dichotomous) · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.68 [0.66, 4.28]
1 study · 41 participants
Very low

Omeprazole vs placebo

Improvement in symptoms in infants · GORD in infants

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Esomeprazole vs placebo

Adverse events ‐ not reported · GORD in infants

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Esomeprazole vs placebo

pH indices ‐ not measured · GORD in infants

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Esomeprazole vs placebo

Endoscopic metrics ‐ not measured · GORD in infants

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

Improvement in symptoms · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 127 participants
Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

Adverse events · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 127 participants
Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

Endoscopic improvement (dichotomous) · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 127 participants
Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

pH indices ‐ not measured · GORD in children over 1 year of age

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

Improvement in symptoms · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

Adverse events · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

Improvement in pH indices ‐ not measured · GORD in children over 1 year of age

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omeprazole vs placebo

Adverse events ‐ not reported · GORD in infants

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

Endoscopic metrics ‐ not measured · GORD in children over 1 year of age

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found